Efficacy of $^{11}$C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with $^{18}$F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease

A protocol for systematic review and meta analysis

Lei Jiang, PhD, Xixian Wang, MD, Pengtao Li, MD, Zhaohai Feng, MD, Xin Shi, PhD, Hua Shao, PhD.

Abstract

Background: Parkinson’s disease (PD) has a high incidence in the elderly, and the late stage seriously affects the daily life of the patients. Most of the initial symptoms of PD are not obvious or atypical, which brings difficulties to the early diagnosis. Replacement therapy and neuroprotection after early diagnosis can significantly improve the prognosis and quality of life of patients. More and more evidence shows that $^{11}$C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography ($^{11}$C-CFT PET) combined with $^{18}$F-fluorodeoxyglucose positron emission tomography ($^{18}$F-FDG PET) can effectively improve the accuracy of early diagnosis. However, there is no consistent conclusion at present. The purpose of this study is to evaluate the efficacy of $^{11}$C-CFT PET combined with $^{18}$F-FDG PET in the diagnosis of early PD.

Methods: We will search 7 electronic databases (PubMed, EMBASE, Web of Science, Cochrane library, PsycINFO, AMED, Scopus), ongoing trials and grey literature to collect related randomized controlled trials and will use Review Manager Software 5.2 and STATA Software 16.0 for analysis and synthesis.

Results: We will integrate the existing randomized controlled trials to evaluate the value of $^{11}$C-CFT PET combined with $^{18}$F-FDG PET in the diagnosis of early PD.

Conclusion: Our study may prove that $^{11}$C-CFT PET combined with $^{18}$F-FDG PET can effectively diagnose early PD.

Registration number: International Prospective Register of Systematic Reviews (PROSPERO): CRD42020203442.

Abbreviations: $^{11}$C-CFT PET = $^{11}$C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography, $^{18}$F-FDG PET = $^{18}$F-fluorodeoxyglucose positron emission tomography, DAT = dopamine transporter, PD = Parkinson disease.

Keywords: $^{11}$C-CFT PET, $^{18}$F-fluorodeoxyglucose positron emission tomography, diagnosis, early Parkinson’s disease, meta analysis, protocol, systematic review

1. Introduction

Parkinson’s disease (PD), which affects about 2% of people over the age of 60, is a common neurodegenerative disease.[1] The pathological feature is the degeneration and loss of dopaminergic neurons in substantia nigra, resulting in an irreversible decrease in dopamine content.[2] PD developed irreversibly with time, and most of them died of complications such as pneumonia and urinary tract infection after long-term bedridden.[3] Most PD patients have atypical clinical symptoms in the early stage (Hoehn-Yahr I, II). When dopaminergic neurons in substantia nigra are damaged, the brain compensates for the deficiency by increasing the activity of other neurotransmitters. This process is called neuroplasticity. As the disease progresses, the brain’s ability to compensate decreases, leading to the development of motor symptoms such as tremors, rigidity, and bradykinesia.

LJ and XW contributed equally to this work and should be considered co-first authors.

Our study was funded by the Natural Science Foundation of China Autonomous Region (Approval Number: 2020D01C235 and 2020D01C230). The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

*Department of Neurosurgery, †Department of Imaging, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China.

Correspondence: Hua Shao, Department of Imaging, The First Affiliated Hospital of Xinjiang Medical University, No. 137, Liyushan South Road, Urumqi 830054, Xinjiang Uygur Autonomous Region, China (e-mail: 3441463984@qq.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To cite this article: Jiang L, Wang X, Li P, Feng Z, Shi X, Shao H. Efficacy of $^{11}$C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane positron emission tomography combined with $^{18}$F-fluorodeoxyglucose positron emission tomography in the diagnosis of early Parkinson disease: A protocol for systematic review and meta analysis. Medicine 2020;99(3):e23395.

Received: 7 October 2020 / Received in final form: 16 October 2020 / Accepted: 29 October 2020
http://dx.doi.org/10.1097/MD.0000000000023395
nigra are degenerated, dopamine decreases irreversibly, and typical clinical symptoms often indicate that the patient has reached a later stage (Hoehn-Yahr III ∼ V). At this time, the damage of dopaminergic neurons is as high as 30% to 80%, even if the patient is treated in time, the prognosis and quality of life are also very poor. The diagnosis mainly depends on the experience of clinicians, and the symptoms, signs and the efficacy of levodopa treatment are comprehensively evaluated, but there is still a lack of diagnostic gold standard and objective examination index. Early diagnosis of PD is very important, because replacement therapy and neuroprotection after early diagnosis can significantly improve the prognosis and quality of life of patients, but the accuracy of early diagnosis (Hoehn-Yahr I, II) is only 53%. The pathological changes induced by PD are closely related to the changes of glucose metabolism and dopamine transporter (DAT). Many studies have confirmed that PD has its unique PD-related motor pattern (PDRP) imaging in 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging. PDRP, which is related to the decrease of dopamine, can help to detect the degeneration and loss of dopamine in substantia nigra in the early stage, and plays an important role in early diagnosis. DAT is a membrane protein in the presynaptic membrane of dopaminergic neurons, which is positively correlated with the decrease of dopaminergic neurons. 

The purpose of this study was to evaluate the efficacy of 11C-CFT PET combined with 18F-FDG PET in the diagnosis of early PD.

2. Methods and analysis

2.1. Study registering

We have registered the study on PROSPERO (https://www.crd.york.ac.uk/prosporo/). The registration number is CRD42020203442. This study will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines.

2.2. Eligibility criteria

2.2.1. Type of study. We will include randomized controlled trials for the diagnosis of early PD patients through 11C-CFT PET combined with 18F-FDG PET.

| Number | Search Items |
|--------|--------------|
| 1      | Parkinson’s/ |
| 2      | Parkinson’s or Parkinson’s or Parkinsonism or Parkinsonian or PD, ti,ab,cl,ou,kw. |
| 3      | 1 or 2      |
| 4      | 11C-C2b-carbomethoxy-3b-(4-fluorophenyl) tropane positron emission tomography or 11C-CFT-PET-CT or 11C-CFT-PET or 11C-CFT or C-CFT, ti,ab,cl,ou,kw. |
| 5      | 3 and 4     |
| 6      | 18F-fluoro-2-deoxyglucose positron emission tomography or 18F-fluorodeoxyglucose PET-CT or 18F-FDG PET-CT or 18F-FDG-PET or 18F-fluorodeoxyglucose or 18F-FDG or fluorodeoxyglucose, ti,ab,cl,ou,kw. |
| 7      | 5 and 6     |
| 8      | (randomized controlled trial or randomized or random or RCT), ti,ab,cl,ou,kw. |
| 9      | 7 and 8     |
| 10     | Remove duplicates from 9 |

RCT = randomized controlled trials.

2.2.2. Type of participants. All patients diagnosed with early PD (Hoehn-Yahr I, II) will be included in this study.

2.2.3. Type of index test. Index test: early PD (Hoehn-Yahr I, II) patients were examined by 11C-CFT PET combined with 18F-FDG PET. We will exclude the combination of 11C-CFT PET, 18F-FDG PET and other tests.

Reference test: early PD that meets the Parkinson’s Disease Society Brain Bank (PDSBB) Parkinson diagnostic criteria will be used as the control group.

2.2.4. Outcome measurements. Outcomes are Sensitivity, Specificity, Hierarchical summary receiver operating characteristic (HSROC), Area Under the Curve (AUC), Diagnostic odds ratio (DOR), Likelihood ratio (LR).

2.3. Search methods for identification of studies

2.3.1. Electronic data sources. From the beginning to September 25, 2020, we will search 7 electronic databases (PubMed, EMBASE, Web of Science, Cochrane library, PsycINFO, AMED, Scopus).

2.3.2. Other resources. We also search for ongoing trials on the World Health Organization’s International Clinical trial Registration platform. In addition, grey literature such as the health management information database, the OpenSIGLE database and the National Technical Information Service will be searched.

2.4. Search strategy

The search terms will be expanded around: 11C-CFT PET, 18F-FDG PET, diagnosis, early Parkinson’s disease, efficacy and randomized controlled trials. There are no restrictions on race, publication date or language. For example, Table 1 shows our detailed search strategy for PubMed, and the search strategy for other databases will be adjusted according to the characteristics of each database.

2.5. Data collection

2.5.1. Selection of studies. The studies extracted from the database according to the search strategy will be imported into Endnote Software X9.0 for deduplication. Two researchers (LJ and XS) will combine inclusion and exclusion criteria by independently screening the title and abstract of each study. After that, read the full text for a second screening. Two researchers (LJ and XS) will cross-examine the included study. If disagreement arises during this
period, a third researcher (HS) will participate in the discussion and decide whether to include it or not. Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-analysesProtocols flow diagram of the study selection process.

2.5.2. Data extraction and management. Two researchers (XXW and PTL) will independently extract the following data from the included literature: basic information, inclusion criteria, exclusion criteria, participant information, trial and control group details, results, conclusions, and follow-up. The third researcher (ZHF) will verify the data. Contact the author of the document to obtain complete data if necessary.

2.6. Quality assessment

The 2 researchers (LJ and PTL) will use QUADAS-2 to assess the risk of bias in 4 areas: patient selection, indicator testing, reference criteria, and process and timing. If there is any dispute, the third researcher (XXW) will participate in the negotiation and settlement.

2.7. Statistical analysis

We will use Review Manager Software 5.2 and STATA Software 16.0 to analyze the extracted data. Summarize the specific characteristics and research results through the table. We will
estimate outcome as descriptive statistics and 95% confidence intervals, and will perform plots of descriptive forest and summary receiver operating characteristic. Heterogeneity will be checked by $I^2$ statistic. $I^2 \leq 50\%$ suggests low heterogeneity, and Mante-Haenszel fixed-effects model will be used, while $I^2 > 50\%$ indicates significant heterogeneity, and Mante-Haenszel random-effects model will be applied. When the heterogeneity is low, we will conduct a meta-analysis on the basis of a sufficiently qualified study of the same result index. When there is substantial heterogeneity, we will conduct a group analysis to identify its possible sources.

### 2.8. Subgroup analysis
We will conduct a subgroup analysis according to different age of diagnosis, different symptoms and different Hoehn-Yahr grades to observe the possible heterogeneity in the study.

### 2.9. Sensitivity analysis
For studies with a risk of bias, data, and sample size deficiencies, sensitivity analyses are performed to assess robustness if statistically significant heterogeneity exists.

### 2.10. Reporting bias
We will use funnel plots and trim and fill methods to detect report biases.$^{[25,26]}$

### 2.11. Ethics and dissemination
Considering that our study is not related to individual patient data, ethical approval is not necessary. The results of this study will be published in peer-reviewed journals or related conferences to evaluate the efficacy of $^{11}$C-CFT PET combined with $^{18}$F-FDG PET in the diagnosis of early PD.

### 3. Discussion
PD seriously affects the quality of life of the elderly, especially early PD. It is difficult to diagnose PD in the early stage, and there is still lack of diagnostic gold standard and objective examination index. More and more evidence shows that $^{11}$C-CFT PET combined with $^{18}$F-FDG PET can effectively improve the accuracy of early diagnosis, but there is no systematic review or meta analysis. This study is the first time to conduct a systematic review and meta analysis of the efficacy of $^{11}$C-CFT PET combined with $^{18}$F-FDG PET in the diagnosis of early PD. The results of this study will provide reference for clinical practice and promote follow-up research.

### Author contributions
Conceptualization: Lei Jiang, Xixian Wang.
Data management: Xixian Wang, Pengtao Li, Zhaohai Feng.
Funding acquisition: Xixian Wang, Lei Jiang, Hua Shao.
Methodology: Xin Shi.
Software analysis: Lei Jiang.
Supervision: Hua Shao.
Writing – original draft: Lei Jiang.

### References
[1] Poewe W, Seppi K, Tanner Caroline M, et al. Parkinson disease. J Nat Rev Dis Primers 2017;3:17013.
[2] Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. J Neurology 1992;42:1142–6.
[3] Stuart S, Lawson Rachael A, Yarnall Alison J, et al. Pro-Saccades Predict Cognitive Decline in Parkinson’s disease: ICCLE-PD. J Mov Disord 2019;34:1690–8.
[4] Odekerken Vincent JJ, van Laar T, Staal Michel J, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. J Lancet Neurol 2013;12:37–44.
[5] Berg D, Adler Charles H, Bloem Bastaan R, et al. Movement disorder society criteria for clinically established early Parkinson’s disease. J Mov Disord 2018;33:1643–6.
[6] Van Rumund A, Aerts Marjolien B, Esselink Rianne AJ, et al. Parkinson’s Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differential of parkinsonism. J BMC Neurol 2018;18:69.
[7] Abbas Masoom M, Koh WP, Tan EK, et al. Positive predictive value of different methods for identifying Parkinson’s disease cases in an epidemiological study. J Parkinsonism Relat Disord 2018;54:119–20.
[8] Adler Charles H, Beach Thomas G, Hentz Joseph G, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. J Neurology 2014;483:406–12.
[9] Yoo HS, Lee S, Chung SJ, et al. Clinical and striatal dopamine transporter predictors of mild behavioral impairment in drug-naive Parkinson Disease. J Clin Nucl Med 2020.
[10] Shin HW, Chung SJ, Lee S, et al. Dysautonomia is linked to striatal dopamine deficits and regional cerebral perfusion in early Parkinson disease. J Clin Nucl Med 2020;45:342–8.
[11] Palermo G, Giannoni S, Frosini D, et al. Dopamine transporter, age, and motor complications in Parkinson’s disease: a clinical and single-photon emission computed tomography study. J Mov Disord 2020;35:1028–36.
[12] Keegan Rosalie V, Janzen A, Meles Sanne K, et al. Four-year follow-up of $[^{18}$F]fluorodeoxyglucose positron emission tomography-based Parkinson’s disease-related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows progradual progression. J Mov Disord 2020.
[13] Liguori C, Ruffini R, Olivola E, et al. Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and $^{18}$F-AV-1351-related neurodegenerative disorders: a brain $[^{18}$F]FDG PET study. J Parkinsonism Relat Disord 2019;64:97–105.
[14] Zhao F, Zhang B, Gao S, et al. Clinical features, MRI, and $^{18}$F-FDG-PET in differential diagnosis of Parkinson disease from multiple system atrophy. J Brain Behav 2020.
[15] Shin JH, Lee JY, Kim YK, et al. Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. J Neurology 2020.
[16] Shigekiyo T, Arashaka S. Laterality of specific binding ratios on DAT-SPECT for differential diagnosis of degenerative parkinsonian syndromes. J Sci Rep 2020;10:15761.
[17] Brumberg J, Kerstens V, Cselényi Z, et al. Simplified quantification of $[^{18}$F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium. J Cereb Blood Flow Metab 2020.
[18] Li W, Lao-Kaim Nick P, Roussakis AA, et al. Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson’s disease. J NeuroImage Clin 2020;28:102499.
[19] Akram H, Wu C, Hyam J, et al. 1-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson’s disease. J Mov Disord 2017;10:784–83.
[20] Rosano C, Merli Andrea L, Rosso Andrea L, et al. Influence of striatal dopamine, cerebral small vessel disease, and other risk factors on age-related parkinsonian motor signs. J Gerontol A Biol Sci Med Sci 2020;75:696–701.
[21] Huang T, Wang H, Tang G, et al. The influence of residual nor-($^{11}$C) CFT in 11C CFT injection on the Parkinson disease diagnosis: a 11C CFT PET study. J Clin Nucl Med 2012;37:743–7.
[22] Appel L, Jonasson M, Danfors T, et al. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. J Nucl Med 2015;56:234–42.
[23] Zhang YF, Wang XY, Cao L, et al. Effects of hypoxic-ischemic brain injury on striatal dopamine transporter in newborn piglets: evaluation of $^{11}$C-CFT PET/CT for DAT quantification. J Nucl Med Biol 2011;38:1205–12.
[24] David M, Larissa S H, Mike C, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. J Systematic Reviews 2015.
[25] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. J BMJ 2000;320:1574–7.
[26] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. J BMJ 1997;315:629–34.
[27] Whiting Penny F, Rutjes Anne WS, Westwood Marie E, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. J Ann Intern Med 2011;155:529–36.